Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
1. A composition comprising: a splice modulating oligonucleotide (SMO) sequence that specifically binds a complementary sequence of a pre-mRNA that undergoes splicing to form a mRNA encoding a glutamate activated α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit (GluR), wherein said SMO decreases expression of the flip isoform of said GluR in a cell, wherein said SMO comprises SEQ ID NO: 143 and is selected from SEQ ID Nos 65, 66, 68, 69, 83, 84, 85, 102, 103, 104 and 122, and wherein at least one nucleotide in said SMO contains a non-naturally occurring modification.
2. The composition of claim 1 , said non-naturally occurring modification comprising one or more modification selected from phosphorothioate 2′-O-methyl nucleotides, 2′-O-methoxyethyl (2′ MOE) nucleotides, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), phosphorodiamidate morpholinos (PMOs), and cholesterol conjugates.
3. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
4. A composition comprising: a splice modulating oligonucleotide (SMO) sequence that specifically binds a complementary sequence of a pre-mRNA that undergoes splicing to form a mRNA encoding a glutamate activated α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit (GluR), wherein said SMO decreases expression of the flip isoform of said GluR in a cell, wherein said SMO comprises SEQ ID NO: 228 and is selected from SEQ ID Nos 189, 190, 191, 192, 193, 198, 200, 201, 208, 209, 210, 218 and 219, and wherein at least one nucleotide in said SMO contains a non-naturally occurring modification.
5. The composition of claim 4 , said non-naturally occurring modification comprising one or more modification selected from phosphorothioate 2′-O-methyl nucleotides, 2′-O-methoxyethyl (2′ MOE) nucleotides, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), phosphorodiamidate morpholinos (PMOs), and cholesterol conjugates.
6. The composition of claim 4 , further comprising a pharmaceutically acceptable carrier.
7. The composition of claim 2 , further comprising a pharmaceutically acceptable carrier.
8. The composition of claim 5 , further comprising a pharmaceutically acceptable carrier.